Mark Stein
Columbia University · University of Washington · Seattle Children's Hospital
Built from public records under this name as ClinicalTrials.gov spells it. A name can belong to more than one person, so each section says how its rows were tied to this name. No contact details are shown.
Trials
Studies that name Mark Stein as principal investigator, study chair or study director, newest first. Live from ClinicalTrials.gov, fetched 2026-11-11 23:10 UTC. Open this list on ClinicalTrials.gov
- Ph1/Ph2NCT05682443 · ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPCOncoC4, Inc. · active not recruiting · Metastatic Castration-resistant Prostate Cancer · principal investigator
- Ph4NCT03781752 · Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHDIcahn School of Medicine at Mount Sinai · unknown · ADHD, Attention Deficit Hyperactivity Disorder · principal investigator
- Ph4NCT02255565 · Dose Response Effects of Quillivant XR in Children With ADHD and Autism: A Pilot StudySeattle Children's Hospital · completed · ADHD, Autism · principal investigator
- Ph2NCT01200810 · Bicalutamide and RO4929097 in Treating Patients With Previously Treated Prostate CancerNational Cancer Institute (NCI) · terminated · Adenocarcinoma of the Prostate, Recurrent Prostate Cancer, Stage IV Prostate Cancer · principal investigator
- Ph1NCT00891072 · Gossypol, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by SurgeryNational Cancer Institute (NCI) · completed · Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Contiguous Stage II Adult Burkitt Lymphoma · principal investigator
- Ph2NCT00786682 · Docetaxel and Hydroxychloroquine in Treating Patients With Metastatic Prostate CancerUniversity of Medicine and Dentistry of New Jersey · terminated · Prostate Cancer · principal investigator
- Ph1NCT00496600 · Phase I Study of Patupilone and RAD001University of Medicine and Dentistry of New Jersey · completed · Refractory Malignancy · principal investigator
- Ph3NCT00468273 · A Clinical Study of Intravenous ImmunoglobulinFFF Enterprises · completed · Immunologic Deficiency Syndromes · principal investigator
- Ph2NCT00337077 · Eribulin Mesylate in Treating Patients With Metastatic Prostate Cancer That Did Not Respond to Hormone TherapyNational Cancer Institute (NCI) · completed · Adenocarcinoma of the Prostate, Hormone-refractory Prostate Cancer, Recurrent Prostate Cancer · study chair
- Ph2NCT00323791 · Gemcitabine With or Without Imatinib Mesylate in Treating Patients With Metastatic or Unresectable Kidney CancerUniversity of Medicine and Dentistry of New Jersey · terminated · Kidney Cancer · principal investigator
- Ph2NCT00176605 · Phase II Metronomic Dosing, Etoposide, Cyclophosphamide, D0 Prostate CancerRutgers, The State University of New Jersey · completed · Prostate Cancer · principal investigator
- Ph2NCT00176644 · Phase II Trial of Transdermal Estradiol for Hormone Refractory Prostate CancerUniversity of Medicine and Dentistry of New Jersey · terminated · Prostate Cancer · principal investigator
Grants
NIH projects from RePORTER, fetched 2026-11-11 23:10 UTC. A project is listed only when its grant number is on one of the trials above, or when the awardee institution matches an affiliation the registry gives for this name. 66 other NIH projects list an investigator with the same name at a different institution and are left out. Coverage is US federal funding only; UK and EU funders are not searched yet.
- Defining the role of tumoral MHC Class I Expression in Mediating Colorectal Cancer Racial DisparitiesR01CA264525 · NCI · OHIO STATE UNIVERSITY · fiscal years 2023 to 2026 · $636,262 awarded in 2026Same name and institution; not confirmed by an ID
- Longitudinal Pet Imaging Of Antipsychotic Binding To The Dopamine-3 Receptor In SchizophreniaR01MH139651 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · fiscal years 2026 · $843,322 awarded in 2026Same name and institution; not confirmed by an ID
- 1/2 Treating Mothers with ADHD and their Young Children Via Telehealth: A Hybrid Type I Effectiveness-Implementation TrialR01MH118313 · NIMH · SEATTLE CHILDREN'S HOSPITAL · fiscal years 2019 to 2023 · $661,289 awarded in 2023Same name and institution; not confirmed by an ID
- PROTOCOL REVIEW AND MONITORING SYSTEM (Core 013)P30CA022453 · NCI · WAYNE STATE UNIVERSITY · fiscal years 2016 to 2020 · $75,086 awarded in 2020Same name and institution; not confirmed by an ID
- Research Support for Biomedical Careers at CCNYR25GM056833 · NIGMS · CITY COLLEGE OF NEW YORK · fiscal years 2006 to 2019 · $133,915 awarded in 2019Same name and institution; not confirmed by an ID
- Sequencing Treatments for Mothers with ADHD & Their At-Risk Children: A SMART pilR34MH099208 · NIMH · SEATTLE CHILDREN'S HOSPITAL · fiscal years 2013 to 2015 · $189,326 awarded in 2015Same name and institution; not confirmed by an ID
- Activation of the cyclin D1 promoter by arseniteSC3GM088083 · NIGMS · CITY COLLEGE OF NEW YORK · fiscal years 2009 to 2012 · $114,345 awarded in 2012Same name and institution; not confirmed by an ID
- Analysis of nonsense mediated mRNA decay in DrosophilaR01GM084011 · NIGMS · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · fiscal years 2008 to 2012 · $265,509 awarded in 2012Same name and institution; not confirmed by an ID
- AREA II CANCER AND AGINGG12RR003060 · NCRR · CITY COLLEGE OF NEW YORK · fiscal years 1996 to 2011 · $246,781 awarded in 2011Same name and institution; not confirmed by an ID
- Sub 13 at YaleU54GM075026 · NIGMS · NEW YORK STRUCTURAL BIOLOGY CENTER · fiscal years 2005 to 2009 · $121,674 awarded in 2009Same name and institution; not confirmed by an ID
- Sub-project 9U54GM074958 · NIGMS · RUTGERS, THE STATE UNIV OF N.J. · fiscal years 2005 to 2009 · $1,188,251 awarded in 2009Same name and institution; not confirmed by an ID
- CORE--BRAIN IMAGINGP50MH066171 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · fiscal years 2004 to 2008 · $162,751 awarded in 2008Same name and institution; not confirmed by an ID
- TRANSFORMATION RELATED GENE EXPRESSION IN SV40 INFECTED KERATINOCYTESS06GM008168 · NIGMS · CITY COLLEGE OF NEW YORK · fiscal years 1999 to 2002 · $40,863 awarded in 2002Same name and institution; not confirmed by an ID
- TECHNIQUES FOR S. PNEUMONIAE AND H. INFLUENZA DETECTIONR03AI046227 · NIAID · JOHNS HOPKINS UNIVERSITY · fiscal years 1999 to 2001 · $82,000 awarded in 2001Same name and institution; not confirmed by an ID
- EFFICACY OF INACTIVATED INFLUENZA VACCINE IN HOSPITAL STAFFM01RR000052 · NCRR · JOHNS HOPKINS UNIVERSITY · fiscal years 1998 to 1999 · $20,649 awarded in 1999Same name and institution; not confirmed by an ID
- PROSPECTIVE EVALUATION EFFICACY INACTIVATED INFLUENZA VACCINE IN HOSPITAL STAFFM01RR000722 · NCRR · JOHNS HOPKINS UNIVERSITY · fiscal years 1994Same name and institution; not confirmed by an ID
- PROTEASE INHIBITOR EFFECTS IN EPITHELIAL TRANSFORMATIONR01CA052915 · NCI · CITY COLLEGE OF NEW YORK · fiscal years 1990 to 1993 · $35,070 awarded in 1993Same name and institution; not confirmed by an ID
- ONCOGENE EXPRESSION IN SV40-INFECTED KERATINOCYTESR01CA027869 · NCI · CITY COLLEGE OF NEW YORK · fiscal years 1985 to 1989 · $145,311 awarded in 1989Same name and institution; not confirmed by an ID
- MONOCLONAL ANTIBODIES IN STUDYING PLATELET PHYSIOLOGYK11HL001544 · NHLBI · STATE UNIVERSITY NEW YORK STONY BROOK · fiscal years 1985 to 1987 · $20,925 awarded in 1987Same name and institution; not confirmed by an ID
NIH grants that fund their trials
These grant numbers are on the registry records of the trials above. They fund the trial, often through a cooperative group or network, and their principal investigator is usually someone else.
- Carboxylesterase 1 Genetic Variation and Methylphenidate in ADHDR01HD093612 · NICHD · UNIVERSITY OF FLORIDA · PI JOHN S MARKOWITZ, Haojie Zhu · fiscal years 2018 to 2022Named on NCT03781752
- Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis (U01)U01CA132194 · NCI · RBHS -CANCER INSTITUTE OF NEW JERSEY · PI ROBERT S. DIPAOLA · fiscal years 2008 to 2013Named on NCT00891072
- Cancer Center AdministrationP30CA072720 · NCI · RUTGERS BIOMEDICAL AND HEALTH SCIENCES · PI John Pounardjian · fiscal years 1997 to 2026
- Eastern Cooperative Oncology Group Operations OfficeU10CA021115 · NCI · FRONTIER SCI & TECHNOLOGY RSCH FDN, INC · PI ROBERT L COMIS · fiscal years 1985 to 2013Named on NCT00337077
Most cited trial papers
Clinical-trial papers with this author name, ranked by citations from NIH iCite, fetched 2026-11-11 23:10 UTC. The ranking covers the 200 most relevant of 439 PubMed records, and a shared surname and initials can bring in a namesake. All 439 on PubMed
- 843 citationsRCR 33.7
- Phase II and biomarker study of the dual MET/VEGFR2 inhibitor foretinib in patients with papillary renal cell carcinoma.J Clin Oncol · 2013382 citationsRCR 9.9
- Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis.J Allergy Clin Immunol · 2006341 citationsRCR 8.3
- Laparoscopic sleeve gastrectomy--volume and pressure assessment.Obes Surg · 2008295 citationsRCR 10.7
- Enfortumab vedotin after PD-1 or PD-L1 inhibitors in cisplatin-ineligible patients with advanced urothelial carcinoma (EV‑201): a multicentre, single-arm, phase 2 trial.Lancet Oncol · 2021256 citationsRCR 13.3
- 245 citationsRCR 14.1
- Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced colorectal carcinoma.PLoS One · 2017236 citationsRCR 6.4
- Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans.N Engl J Med · 2018236 citationsRCR 12.4
- Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with recurrent carcinoma of the anal canal.Ann Oncol · 2017201 citationsRCR 5.8
- 188 citationsRCR 10.3